Clinical Trials
17 trialsNCT05395741 2026-03-25
Regbone
Institute of Mother and Child, Warsaw, Poland
Phase 1/2 Active not recruiting
NCT02386397 2026-03-12
BREGO
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT07137390 2026-03-11
A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT03828799 2026-02-27
FOLFIRINOX-R
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT05672316 2026-01-28
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT04781192 2026-01-23
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
University of Kansas Medical Center
Phase 1/2 Active not recruiting
NCT03657641 2025-07-04
Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
University of Southern California
Phase 1/2 Active not recruiting
NCT04170556 2024-09-03
GOING
Fundacion Clinic per a la Recerca Biomédica
Phase 1/2 Completed
NCT04625907 2024-05-23
FaR-RMS
University of Birmingham
Phase 1/2 Recruiting
NCT03722108 2023-10-16
REGIRI
UNICANCER
Phase 1/2 Terminated
NCT03475953 2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2 Unknown
NCT05426811 2022-06-29
Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients
China Medical University, China
Phase 1/2 Unknown
NCT04110093 2020-12-30
Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer
Shanghai Changzheng Hospital
Phase 1/2 Unknown
NCT01896856 2020-10-06
Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT03946917 2020-05-12
JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer
Sun Yat-sen University
Phase 1/2 Unknown
NCT02406170 2019-10-22
REPEAT
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1/2 Completed
NCT04008511 2019-07-05
Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer
China Medical University, China
Phase 1/2 Unknown